CD30 and CD30-targeted therapies in Hodgkin lymphoma and other B cell lymphomas
G Bhatt, K Maddocks, B Christian - Current hematologic malignancy …, 2016 - Springer
G Bhatt, K Maddocks, B Christian
Current hematologic malignancy reports, 2016•SpringerEvolution of cancer therapeutics has resulted in the development of agents with varying
mechanisms of selective target inhibition. One such therapeutic approach is utilizing
antibody-drug conjugates (ADCs), the combination of a cytotoxic agent linked with a
monoclonal antibody, to achieve localization of the target and internalization of the cytotoxic
agent in order to maximize efficacy with fewer toxicities. This review focuses on CD30 as a
therapeutic target and the development and clinical activity of the ADC brentuximab vedotin …
mechanisms of selective target inhibition. One such therapeutic approach is utilizing
antibody-drug conjugates (ADCs), the combination of a cytotoxic agent linked with a
monoclonal antibody, to achieve localization of the target and internalization of the cytotoxic
agent in order to maximize efficacy with fewer toxicities. This review focuses on CD30 as a
therapeutic target and the development and clinical activity of the ADC brentuximab vedotin …
Abstract
Evolution of cancer therapeutics has resulted in the development of agents with varying mechanisms of selective target inhibition. One such therapeutic approach is utilizing antibody-drug conjugates (ADCs), the combination of a cytotoxic agent linked with a monoclonal antibody, to achieve localization of the target and internalization of the cytotoxic agent in order to maximize efficacy with fewer toxicities. This review focuses on CD30 as a therapeutic target and the development and clinical activity of the ADC brentuximab vedotin in Hodgkin lymphoma (HL) and other B cell lymphomas.
Springer